Abstract:
OBJECTIVE To explore the therapeutic effects of apoptotic vesicles (ApoVs) derived from human umbilical cord mesenchymal stem cells (hUCMSCs) on lipopolysaccharide (LPS)-induced injury in mouse alveolar macrophages (MH-S) and acute lung injury (ALI).
METHODS In cell experiments, MH-S cells were induced to injury with 100 ng/ml LPS and treated with different concentrations of ApoVs (104~108 particles/ml) for 24 hours. Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of inflammatory cytokines interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α). In animal experiments, a mouse ALI model was established by intratracheal injection of 5 mg/kg LPS. Two hours later, different doses of ApoVs (10, 20, 40 μg/mouse) were injected intravenously through the tail vein. Samples were collected after 24 hours, and the pathological changes in lung tissues were observed through hematoxylin-eosin staining. RT-qPCR was used to detect inflammatory cytokines, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lung tissues. Enzyme-linked immunosorbent assay (ELISA) was employed to detect the levels of inflammatory cytokines in bronchoalveolar lavage fluid (BALF) and serum.
RESULTS Cell experiments showed that ApoVs at concentrations of 106and 107 particles/ml reduced the expression of IL-1β, IL-6 and TNF-α in MH-S cells (P < 0.05), while no significant improvement was observed in the 108 particles/ml group. Animal experiments revealed that the pathological scores of lung tissues in the group treated with ApoVs at doses of 10 μg/mouse and 20 μg/mouse significantly reduced (P < 0.05), as well as the expression of IL-1β, IL-6, TNF-α, iNOS and COX-2 in lung tissue, BALF and serum (P < 0.05), whereas no significant improvement was observed in the 40 μg/mouse group.
CONCLUSIONS ApoVs derived from hUCMSCs can effectively alleviate LPS-induced infectious ALI at both the cellular and animal levels. The therapeutic effect does not increase with increasing dose, indicating the existence of an optimal concentration window.